首页> 外文期刊>Stem cells translational medicine. >A Massive Suspension Culture System With Metabolic Purification for Human Pluripotent Stem Cell-Derived Cardiomyocytes
【24h】

A Massive Suspension Culture System With Metabolic Purification for Human Pluripotent Stem Cell-Derived Cardiomyocytes

机译:大规模悬浮培养系统的代谢纯化人多能干细胞衍生的心肌细胞。

获取原文
       

摘要

Cardiac regenerative therapy with human pluripotent stem cells (hPSCs), such as human embryonic stem cells and induced pluripotent stem cells, has been hampered by the lack of efficient strategies for expanding functional cardiomyocytes (CMs) to clinically relevant numbers. The development of the massive suspension culture system (MSCS) has shed light on this critical issue, although it remains unclear how hPSCs could differentiate into functional CMs using a MSCS. The proliferative rate of differentiating hPSCs in the MSCS was equivalent to that in suspension cultures using nonadherent culture dishes, although the MSCS provided more homogeneous embryoid bodies (EBs), eventually reducing apoptosis. However, pluripotent markers such as Oct3/4 and Tra-1-60 were still expressed in EBs 2 weeks after differentiation, even in the MSCS. The remaining undifferentiated stem cells in such cultures could retain a strong potential for teratoma formation, which is the worst scenario for clinical applications of hPSC-derived CMs. The metabolic purification of CMs in glucose-depleted and lactate-enriched medium successfully eliminated the residual undifferentiated stem cells, resulting in a refined hPSC-derived CM population. In colony formation assays, no Tra-1-60-positive colonies appeared after purification. The nonpurified CMs in the MSCS produced teratomas at a rate of 60%. However, purified CMs never induced teratomas, and enriched CMs showed proper electrophysiological properties and calcium transients. Overall, the combination of a MSCS and metabolic selection is a highly effective and practical approach to purify and enrich massive numbers of functional CMs and provides an essential technique for cardiac regenerative therapy with hPSC-derived CMs.
机译:缺乏将功能性心肌细胞(CMs)扩展至临床相关数量的有效策略,阻碍了使用人类多能干细胞(hPSC)(例如人类胚胎干细胞和诱导性多能干细胞)进行的心脏再生治疗。大规模悬浮培养系统(MSCS)的开发为这个关键问题提供了线索,尽管尚不清楚hPSC如何使用MSCS分化为功能性CM。尽管MSCS提供了更多的均质胚状体(EB),最终减少了细胞凋亡,但MSCS中hPSC的分化率与使用非贴壁培养皿的悬浮培养中的增殖率相同。然而,分化后2周,即使在MSCS中,多能性标志物如Oct3 / 4和Tra-1-60仍在EB中表达。此类培养物中剩余的未分化干细胞可以保留强大的畸胎瘤形成潜能,这对于hPSC衍生的CM的临床应用而言是最糟糕的情况。在葡萄糖缺乏和富含乳酸的培养基中对CMs进行代谢纯化,成功消除了残留的未分化干细胞,从而产生了精制的hPSC衍生的CM群体。在菌落形成测定中,纯化后没有出现Tra-1-60阳性菌落。 MSCS中未纯化的CM产生畸胎瘤的比率为60%。但是,纯化的CM从未诱发畸胎瘤,而富集的CM显示出适当的电生理特性和钙瞬变。总体而言,将MSCS和代谢选择相结合是纯化和丰富大量功能性CM的高效实用方法,并为源自hPSC的CM的心脏再生治疗提供了一项必不可少的技术。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号